tirzepatide and nafld Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2 Retatrutide vs. Tirzepatide: The Next-Gen

NAC has been shown to successfully cross the blood-brain barrier and raise glutathione levels in the brainreducing oxidative stress and protecting the brain from free radical neuronal damage

Compounded medications are non-FDA-approved preparations prepared by state-licensed compounding pharmacies and are not generic versions of, nor the same as, Ozempic, Wegovy, Mounjaro, or Zepbound

GIP receptors influence energy expenditure and fat breakdown differently than GLP-1 receptors alone

M1 macrophages are pro-inflammatory, useful in the very early stages of healing for clearing debris but destructive if they persist

This enhanced incretin effect contributes significantly to the metabolic benefits observed after bariatric surgery, including improved glycemic control independent of weight loss